²Ä 2111 ´Á

108 / 4. 22 ~ 4. 28

¡@

­¹ÃĸpÁ|¿ì¡uÃÄ«~¦uÅ@¤Ñ¨Ï-ÃÄ«~AI·s¥@¥N ´N¬OÃÄGood¡v°OªÌ·|

»sÃÄÂÔ¦u6G³W½d ¦uÅ@¥ÎÃĦw¥þ

¡@

¡ô­¹Ãĸp©ó4¤ë17¤éÁ|¿ì¡uÃÄ«~¦uÅ@¤Ñ¨Ï¡ÐÃÄ«~AI·s¥@¥N ´N¬OÃÄGood¡v°OªÌ·|¡C

¡ô­¹Ãĸp¡u¦èÃÄ¡BÂåÀø¾¹§÷¡B¤ÆùÛ«~³\¥iÃÒ¬d¸ß¨t²Î¡v¡C

¡i¥»¥Z°T¡j

 

ÀHµÛ¥Á²³¥ÎÃÄ·NÃÑ°ªº¦¡A­¹«~ÃĪ«ºÞ²z¸p©ó4¤ë17¤éÁ|¿ì¡uÃÄ«~¦uÅ@¤Ñ¨Ï¡ÐÃÄ«~AI·s¥@¥N ´N¬OÃÄGood¡v°OªÌ·|¡A»¡©úÃÄ«~¤w¶i¤JAI·s¥@¥N¡A¥Á²³¥i³z¹L©x¤è¬d¸ß¨t²Î¨ú±oÃÄ«~©Ò¦³ªº¸ê°T¡C


ÃÄ«~ªº»s³y¥Í²£¹Lµ{­¹Ãĸp¦p¦ó¶i¦æ§âÃö¡H¥Á²³¸Ó¦p¦ó½T©w¨ú±oªºÃÄ«~¬O³q¹L­¹Ãĸp®Ö­ãªº¡H­¹ÃĸpÃÄ«~²Õ¬ìªøªL·Nµ®ªí¥Ü¡AÃÄ«~¶i¤JAI·s¥@¥N¡A§Y«ü¥ÎÃÄ¥iªñ©Ê¡]Accessibility¡^»P´¼¼z¬ì§Þ¡]Intelligence¡^ªºµ²¦X¡C­¹Ãĸp±qÃÄ«~«DÁ{§É¸ÕÅç¡BÁ{§É¸ÕÅç¡B¤W¥«¼f¬d¡B¥Í²£»s³y¡B¹B¾P¦Ü¤W¥««áºÊ±±¡A¥þ­±±j¤Æ´¼¼z¬ì§Þ¤§¹B¥Î¡A¥H´£¤ÉÃÄ«~¥iªñ©Ê¡C


ÃÄ«~±q¶}µo¨ì¤W¥«¡A¤j¬ù­n¤Q¦~ªº®É¶¡¡A¶}µoªÌ¡B¬ãµoªÌ³£­n¿í¦u6G³W½d¡A¥]¬AÀu¨}¹êÅç«Ç¾Þ§@³W½d¡]Good Laboratory Practice, GLP¡^¡BÀu¨}Á{§É¸ÕÅç³W½d¡]Good Clinical Practice, GCP¡^¡BÃÄ«~Àu¨}»s³y³W½d¡]Good Manufacturing Practice, GMP¡^¡BÃÄ«~Àu¨}¹B¾P§@·~³W½d¡]Good Distribution Practice, GDP¡^¡BÃÄ«~Àu¨}¦w¥þºÊµø³W½d ¡]Good Pharmacovigilance Practice, GPvP¡^¡BÃÄ«~Àu¨}¬dÅçµn°OºÞ²z¡]Good Registration Management, GRM¡^µ¥¡A«ùÄò½T«OÃÄ«~«~½è¡B¦w¥þ¤ÎÀø®Ä¡A¥H¦uÅ@¥þ¥Á¥ÎÃĦw¥þ¡C


­¹Ãĸpªí¥Ü¡A³q¹L­¹Ãĸp®Ö­ãªºÃÄ«~¡A·|¦³³\¥iÃÒ¦r¸¹¡AÃÄ®v¥i±Ð¾É¥Á²³¦bÃÄ«~ªº¥~²°¥]¸Ë¡B¼ÐÅҤλ¡©ú®Ñ(¥é³æ)³£¥i¥H¬Ý¨ì³\¥iÃÒ¦r¸¹¡A¥Á²³¥i©ó­¹Ãĸp¡u¦èÃÄ¡BÂåÀø¾¹§÷¡B¤ÆùÛ«~³\¥iÃÒ¬d¸ß¨t²Î¡v¡]http://www.fda.gov.tw/mlms/H0001.aspx¡^¿é¤JÃÄ«~¡u³\¥iÃÒ¦r¸¹¡v©Î¤¤¡B­^¤å¡u«~¦W¡v¡A§Y¥i¬d¸ßÃÄ«~¡B¥é³æ¡BÃIJ°¥~Æ[¡B¦¨¤Àµ¥ÃÄ«~¸ê°T¡A¥t¥~¤]¥i¬d¸ßÃÄ«~¤§­­¨î¶µ¥Ø¡A¥]¬AºÞ¨î¶i¤f¡B·sÃĺʵø¡B­­´Áµù¾P¡B­­Âå°|¨Ï¥Î¡BºÊµø¤¤·sÃÄ¡B­ì®Æ¥¼¨ú±oPIC/S GMP®Ö­ã¨ç¤£±o»s³yµ¥¥ÎÃĸê°T¡A¹ï¦Û§Ú¥ÎÃÄ«~¶µ¦³§ó²`ªº·§©À¡C

 

¦^­º­¶